U.S., Jan. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07354516) titled 'Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension' on Jan. 17.
Brief Summary: Firecrest study is evaluating the intraocular pressure (IOP)-lowering effect, safety, and tolerability of Qlaris' preservative free [PF], fixed-dose combination [FDC] investigational product (IP) in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Study Start Date: Feb. 20
Study Type: INTERVENTIONAL
Condition:
OAG - Open-Angle Glaucoma
OHT - Ocular Hypertension
Intervention:
COMBINATION_PRODUCT: QLS-111-FDC
QLS-111-FDC, a PF FDC administered by topical ophthalmic (TO) application for 14 days in the evening (QPM)...